Senti Biosciences (SNTI) Total Non-Current Liabilities (2021 - 2025)

Senti Biosciences has reported Total Non-Current Liabilities for 5 years, with the latest figure at $37.5 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 10.71% year-over-year to $37.5 million; the trailing twelve-month figure through Dec 2025 stood at $37.5 million (down 10.71% YoY), and the FY2025 full-year result was $37.5 million, down 10.71% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $37.5 million, up from $37.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $53.3 million in Q4 2022, with the low at $36.3 million in Q2 2025.
• Average Total Non-Current Liabilities over 5 years is $43.6 million, with a median of $43.4 million recorded in 2023.
• Year-over-year, Total Non-Current Liabilities surged 46.73% in 2022 and decreased 20.04% in 2024.
• Tracing SNTI's Total Non-Current Liabilities over 5 years: stood at $36.3 million in 2021, then jumped by 46.73% to $53.3 million in 2022, then dropped by 1.37% to $52.6 million in 2023, then declined by 20.04% to $42.0 million in 2024, then dropped by 10.71% to $37.5 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $37.5 million (Q4 2025), $37.0 million (Q3 2025), and $36.3 million (Q2 2025), per Business Quant data.

Peer Comparison